Extensive stage small cell lung cancer is extremely aggressive sub-type of small cell lung cancer. Small cell lung itself is a sub-type of lung cancer which accounts for less than 20% cases. The treatment of extensive stage small cell lung cancer has been extremely challenging owing to poor survival rate of the patients. The prevalence of extensive stage small lung cancer is estimated to increase in five of the seven major markets included in the study.

1. 1
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
E
X
T
E
N
S
I
V
E
S
T
A
G
E
S
M
A
L
L
C
E
L
L
L
U
N
G
C
A
N
C
E
R
M
A
R
K
E
T
res
Focus on Epidemiology, Product, and
Region
Analysis and Forecast: 2022-2032
September 2022
Extensive Stage
Small Cell Lung
Cancer Market -
A Global and
Regional Analysis
Table of Content

2. 2
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
E
X
T
E
N
S
I
V
E
S
T
A
G
E
S
M
A
L
L
C
E
L
L
L
U
N
G
C
A
N
C
E
R
M
A
R
K
E
T
BIS Research is a leading market intelligence and technology research company. BIS Research publishes in-
depth market intelligence reports focusing on the market estimations, technology analysis, emerging high-
growth applications, deeply segmented granular country-level market data and other important market
parameters useful in the strategic decision making for senior management. BIS Research provides multi-client
reports, company profiles, databases, and custom research services.
Copyright © 2022 BIS Research Inc.
All Rights Reserved. This document contains highly confidential information and is the sole property of BIS
Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this
document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people
or organization concerned. It may not be accessed by or offered whether for sale or otherwise to any third
party.

3. 3
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
E
X
T
E
N
S
I
V
E
S
T
A
G
E
S
M
A
L
L
C
E
L
L
L
U
N
G
C
A
N
C
E
R
M
A
R
K
E
T
Table of Content
Executive Summary ........................................................................ 17
1. Market Definition ...................................................................... 25
1.1 Inclusion and Exclusion Criteria ....................................................................25
2. Research Scope....................................................................... 26
2.1 Target Audience...............................................................................................27
2.2 Key Questions Answered in the Report ........................................................27
3. Research Methodology............................................................. 28
3.1 Global Extensive Stage Small Cell Lung Cancer Market: Research
Methodology ....................................................................................................28
3.2 Primary Data Sources .....................................................................................29
3.3 Secondary Data Sources ................................................................................30
3.4 Target Patient Pool Estimation Model ...........................................................30
3.5 Criteria for Company Profiling........................................................................31
4. Markets.................................................................................... 32
4.1 Market Overview ..............................................................................................33
4.1.1 Market Landscape .......................................................................................33
4.1.1.1 Strategic Activities............................................................................................34
4.1.1.2 Regional Distribution of Companies .................................................................35
4.1.2 Market Dynamics.........................................................................................36
4.1.2.1 Market Drivers..................................................................................................36
4.1.2.1.1 Introduction of Immune Checkpoint Inhibitors in Combination with Platinum-
Based Chemotherapy as Mainstay Treatment........................................................ 36
4.1.2.1.2 Next-Generation Sequencing is Helping in Identifying New Molecular Targets
................................................................................................................................. 38
4.1.2.1.3 Need of Potential Treatments to Improve Quality of Life of Extensive Stage
Small Cell Lung Cancer Patients ............................................................................ 43
4.1.2.2 Market Restraints.............................................................................................43
4.1.2.2.1 Lack of Early Detection Methods for Extensive Stage Small Cell Lung Cancer
................................................................................................................................. 43

4. 4
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
E
X
T
E
N
S
I
V
E
S
T
A
G
E
S
M
A
L
L
C
E
L
L
L
U
N
G
C
A
N
C
E
R
M
A
R
K
E
T
4.1.2.2.2 Poor Disease Prognosis of Extensive Stage Small Cell Lung Cancer .................... 43
4.1.2.3 Opportunities....................................................................................................44
4.1.2.3.1 Approval of Immune Checkpoint Inhbitors as Combination Therapy Broadens
the Horizon.............................................................................................................. 44
4.1.2.3.2 Lack of Approved Treatments for Extensive Stage Small Cell Lung Cancer
Relapsed Patients ................................................................................................... 44
5. Indication ................................................................................. 45
5.1 Extensive Stage Small Cell Lung Cancer (ES-SCLC) ...................................46
5.1.1 Disease Overview........................................................................................46
5.1.2 Causes and Risk Factors............................................................................46
5.1.3 Disease Pathophysiology ...........................................................................47
5.1.3.1 Disease Staging...............................................................................................48
5.1.4 Symptoms....................................................................................................48
5.1.5 Treatment Landscape .................................................................................49
5.1.5.1 Treatment Overview.........................................................................................49
5.1.5.2 Treatment Types..............................................................................................50
5.1.5.3 Treatment Guidelines for Extensive Stage Small Cell Lung Cancer Patients
.........................................................................................................................52
5.1.5.4 Treatment Algorithm.........................................................................................54
5.1.6 Unmet Needs ...............................................................................................56
5.1.6.1 Lack of Therapeutic Efficacy of the Existing Treatments ..................................56
5.1.6.2 Treatment-Related Side Effects Impacting Overall Quality of Life ....................56
5.1.7 Patient Journey............................................................................................56
6. Region ..................................................................................... 58
6.1 U.S.....................................................................................................................60
6.2 U.K. ...................................................................................................................63
6.3 Germany ...........................................................................................................65
6.4 France...............................................................................................................67
6.5 Italy ...................................................................................................................69
6.6 Spain.................................................................................................................70

5. 5
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
E
X
T
E
N
S
I
V
E
S
T
A
G
E
S
M
A
L
L
C
E
L
L
L
U
N
G
C
A
N
C
E
R
M
A
R
K
E
T
6.7 Japan ................................................................................................................74
7. Products .................................................................................. 76
7.1 Global Extensive Stage Small Cell Lung Cancer Market Pipeline
Analysis (by Phase).........................................................................................77
7.1.1 Development Phase ....................................................................................77
7.1.2 Drug Class ...................................................................................................77
7.1.3 Route of Administration (RoA)...................................................................78
7.1.4 Monotherapy/Combination Therapy Type.................................................79
7.2 Marketed Products ..........................................................................................86
7.2.1 Zepzelca (Lurbinectedine) ..........................................................................87
7.2.1.1 Overview..........................................................................................................87
7.2.1.2 Commercial Overview ......................................................................................88
7.2.1.2.1 Strategic Activities.................................................................................................... 89
7.2.1.2.2 Regulatory Overview................................................................................................ 89
7.2.1.3 Clinical Overview..............................................................................................90
7.2.2 Cosela (Trilaciclib).......................................................................................91
7.2.2.1 Overview..........................................................................................................91
7.2.2.2 Commercial Overview ......................................................................................91
7.2.2.2.1 Strategic Activities.................................................................................................... 92
7.2.2.2.2 Regulatory Overview................................................................................................ 92
7.2.2.3 Clinical Overview..............................................................................................93
7.2.3 Tecentriq (Atezolizumab)............................................................................93
7.2.3.1 Overview..........................................................................................................93
7.2.3.2 Commercial Overview ......................................................................................94
7.2.3.3 Clinical Overview..............................................................................................95
7.2.4 Imfinzi (Durvalumab)...................................................................................96
7.2.4.1 Overview..........................................................................................................96
7.2.4.2 Commercial Overview ......................................................................................97
7.2.4.3 Clinical Overview..............................................................................................98
7.3 Promising Products in Development .............................................................99

6. 6
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
E
X
T
E
N
S
I
V
E
S
T
A
G
E
S
M
A
L
L
C
E
L
L
L
U
N
G
C
A
N
C
E
R
M
A
R
K
E
T
7.3.1 HLX10 (Serplulimab/Hansizhuang) ..........................................................100
7.3.1.1 Overview........................................................................................................100
7.3.1.2 Commercial Overview ....................................................................................100
7.3.1.2.1 Regulatory Overview.............................................................................................. 100
7.3.1.3 Clinical Overview............................................................................................101
7.3.2 Socazolimab (ZKAB001) ...........................................................................104
7.3.2.1 Overview........................................................................................................104
7.3.2.2 Commercial Overview ....................................................................................104
7.3.2.2.1 Regulatory Overview.............................................................................................. 104
7.3.2.3 Clinical Overview............................................................................................105
7.3.3 SHR-1316 (Adebrelimab)...........................................................................106
7.3.3.1 Overview........................................................................................................106
7.3.3.2 Commercial Overview ....................................................................................107
7.3.3.2.1 Regulatory Overview.............................................................................................. 107
7.3.4 Tislelizumab...............................................................................................109
7.3.4.1 Overview........................................................................................................109
7.3.4.2 Commercial Overview ....................................................................................110
7.3.4.3 Clinical Overview............................................................................................110
8. Competitive Benchmarking and Company Profiles .................. 111
8.1 F. Hoffmann-La Roche Ltd............................................................................112
8.1.1 Company Overview ...................................................................................112
8.1.2 Role of F. Hoffmann-La Roche Ltd in Global Extensive Stage Small
Cell Lung Cancer Market ..........................................................................112
8.1.3 Product Portfolio .......................................................................................113
8.1.4 Key Competitors of the Company............................................................113
8.1.5 Financials...................................................................................................114
8.1.6 Key Insights about the Financial Health of the Company......................115
8.1.7 Business Strategies ..................................................................................116
8.1.8 Corporate Strategies.................................................................................116
8.1.9 Analyst’s Perspective ...............................................................................116

7. 7
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
E
X
T
E
N
S
I
V
E
S
T
A
G
E
S
M
A
L
L
C
E
L
L
L
U
N
G
C
A
N
C
E
R
M
A
R
K
E
T
8.2 AstraZeneca PLC...........................................................................................117
8.2.1 Company Overview ...................................................................................117
8.2.2 Role of AstraZeneca PLC in Global Extensive Stage Small Cell Lung
Cancer Market............................................................................................117
8.2.3 Product Portfolio .......................................................................................117
8.2.4 Key Competitors of the Company............................................................118
8.2.5 Financials...................................................................................................118
8.2.6 Key Insights about the Financial Health of the Company......................119
8.2.7 Business Strategies ..................................................................................120
8.2.8 Analyst's Perspective................................................................................120
8.3 Jazz Pharmaceuticals Plc .............................................................................121
8.3.1 Company Overview ...................................................................................121
8.3.2 Role of Jazz Pharmaceuticals Plc in Global Extensive Stage Small
Cell Lung Cancer Market ..........................................................................121
8.3.3 Product Portfolio .......................................................................................122
8.3.4 Key Competitors of the Company............................................................122
8.3.5 Financials...................................................................................................123
8.3.6 Key Insights about the Financial Health of the Company......................123
8.3.7 Business Strategies ..................................................................................124
8.3.8 Corporate Strategies.................................................................................124
8.3.9 Analyst’s Perspective ...............................................................................124
8.4 G1 Therapeutics Inc. .....................................................................................125
8.4.1 Company Overview ...................................................................................125
8.4.2 Role of G1 Therapeutics Inc. in Global Extensive Stage Small Cell
Lung Cancer Market..................................................................................125
8.4.3 Product Portfolio .......................................................................................125
8.4.4 Key Competitors of the Company............................................................126
8.4.5 Financials...................................................................................................126
8.4.6 Key Insights about the Financial Health of the Company......................127
8.4.7 Business Strategies ..................................................................................127

8. 8
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
E
X
T
E
N
S
I
V
E
S
T
A
G
E
S
M
A
L
L
C
E
L
L
L
U
N
G
C
A
N
C
E
R
M
A
R
K
E
T
8.4.8 Corporate Strategies.................................................................................128
8.4.9 Analyst’s Perspective ...............................................................................128
8.5 Shanghai Henlius Biotech, Inc. ....................................................................129
8.5.1 Company Overview ...................................................................................129
8.5.2 Role of Shanghai Henlius Biotech, Inc. in Global Extensive Stage
Small Cell Lung Cancer Market................................................................129
8.5.3 Product Portfolio .......................................................................................130
8.5.4 Key Competitors of the Company............................................................130
8.5.5 Financials...................................................................................................131
8.5.6 Key Insights about the Financial Health of the Company......................131
8.5.7 Business Strategies ..................................................................................132
8.5.8 Analyst’s Perspective ...............................................................................133
8.6 Lee's Pharmaceutical Limited.......................................................................134
8.6.1 Company Overview ...................................................................................134
8.6.2 Role of Lee's Pharmaceutical Limited in Global Extensive Stage
Small Cell Lung Cancer Market................................................................134
8.6.3 Product Portfolio .......................................................................................135
8.6.4 Key Competitors of the Company............................................................135
8.6.5 Financials...................................................................................................136
8.6.6 Key Insights about the Financial Health of the Company......................136
8.6.7 Business Strategies ..................................................................................137
8.6.8 Analyst’s Perspective ...............................................................................137
8.7 Jiangsu Hengrui Pharmaceuticals Co., Ltd.................................................138
8.7.1 Company Overview ...................................................................................138
8.7.2 Role of Jiangsu Hengrui Pharmaceuticals Co., Ltd. in Global
Extensive Stage Small Cell Lung Cancer Market....................................138
8.7.3 Product Portfolio .......................................................................................139
8.7.4 Key Competitors of the Company............................................................142
8.7.5 Financials...................................................................................................142
8.7.6 Key Insights about the Financial Health of the Company......................143

9. 9
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
E
X
T
E
N
S
I
V
E
S
T
A
G
E
S
M
A
L
L
C
E
L
L
L
U
N
G
C
A
N
C
E
R
M
A
R
K
E
T
8.7.7 Business Strategies ..................................................................................143
8.7.8 Corporate Strategies.................................................................................144
8.7.9 Analyst’s Perspective ...............................................................................144
8.8 Beigene Ltd. ...................................................................................................145
8.8.1 Company Overview ...................................................................................145
8.8.2 Role of Beigene Ltd. in Global Extensive Stage Small Cell Lung
Cancer Market............................................................................................145
8.8.3 Product Portfolio .......................................................................................145
8.8.4 Key Competitors of the Company............................................................146
8.8.5 Financials...................................................................................................146
8.8.6 Key Insights about the Financial Health of the Company......................147
8.8.7 Corporate Strategies.................................................................................147
8.8.8 Analyst’s Perspective ...............................................................................148
9. BIS Research Recommendations............................................ 149
9.1 Current Market Scenario ...............................................................................149
9.2 Future Scenario .............................................................................................149
9.3 Key Success Factors and Challenges .........................................................149
9.3.1 Success Factors........................................................................................149
9.3.2 Key Challenges..........................................................................................150

10. 10
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
E
X
T
E
N
S
I
V
E
S
T
A
G
E
S
M
A
L
L
C
E
L
L
L
U
N
G
C
A
N
C
E
R
M
A
R
K
E
T
List of Figures
Figure 1: Extensive Stage Small Cell Lung Cancer Incidence Growth Rate, 2022-2032
Figure 2: Extensive Stage Small Cell Lung Cancer Prevalence Growth Rate, 2022-2032
Figure 3: Leading Drug Class in Clinical Trials for Extensive Stage Small Cell Lung Cancer Market
Figure 4: Global Extensive Stage Small Cell Lung Cancer Market Segmentation
Figure 5: Global Extensive Stage Small Cell Lung Cancer Market Methodology
Figure 6: Primary Research Methodology
Figure 7: Companies Actively Pursuing Clinical Development for Extensive Stage Small Cell Lung Cancer
Figure 8: Number of Strategic Activities
Figure 9: Regional Distribution of Companies
Figure 10: Lung Cancer Types
Figure 11: Disease Pathophysiology
Figure 12: Extensive Stage Small Cell Lung Cancer Treatment Types
Figure 13: Extensive Stage Small Cell Lung Cancer Treatment Algorithm
Figure 14: Extensive Stage Small Cell Lung Cancer Patient Journey
Figure 15: U.S. Incidence for Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 16: U.S. Prevalence of Extensive Stage Small Cell Lung Cancer, 2022-2032
Figure 17: U.K. Incidence for Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 18: U.K. Prevalence of Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 19: Germany Incidence for Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 20: Germany Prevalence of Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 21: France Incidence for Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 22: France Prevalence of Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 23: Italy Incidence for Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 24: Italy Prevalence of Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 25: Spain Incidence for Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 26: Spain Prevalence of Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 27: Japan Incidence for Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 28: Japan Prevalence of Extensive Stage Small Cell Lung Cancer, 2021-2032
Figure 29: Number of Extensive Stage Small Cell Lung Cancer Clinical Trials
Figure 30: Clinical Trials by Drug Class
Figure 31: Clinical Trials by Monotherapy/Combination Type

11. 11
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
E
X
T
E
N
S
I
V
E
S
T
A
G
E
S
M
A
L
L
C
E
L
L
L
U
N
G
C
A
N
C
E
R
M
A
R
K
E
T
Figure 32: Zepzelca (Lurbinectedine) Annual Sales ($Million), 2020 and 2021
Figure 33: Tecentriq Annual Sales ($Million), 2019-2021
Figure 34: Imfinzi Annual Sales ($Million), 2020 and 2021
Figure 35: F. Hoffmann-La Roche Ltd: Product Portfolio
Figure 36: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
Figure 37: F. Hoffmann-La Roche Ltd: Net Revenue (by Segment), $Million, 2019-2021
Figure 38: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
Figure 39: AstraZeneca PLC: Product Portfolio
Figure 40: AstraZeneca PLC: Overall Financials, $Million, 2019-2021
Figure 41: AstraZeneca PLC: Net Revenue (by Region), $Million, 2019-2021
Figure 42: AstraZeneca PLC: R&D Expenditure, $Million, 2019-2021
Figure 43: Jazz Pharmaceuticals Plc: Product Portfolio
Figure 44: Jazz Pharmaceuticals Plc: Overall Financials, $Million, 2019-2021
Figure 45: Jazz Pharmaceuticals Plc: R&D Expenditure, $Million, 2019-2021
Figure 46: G1 Therapeutics Inc.: Product Portfolio
Figure 47: G1 Therapeutics Inc.: Overall Financials, $Million, 2019-2021
Figure 48: G1 Therapeutics Inc.: R&D Expenditure, $Million, 2019-2021
Figure 49: Shanghai Henlius Biotech, Inc.: Product Portfolio
Figure 50: Shanghai Henlius Biotech, Inc.: Overall Financials, $Million, 2019-2021
Figure 51: Shanghai Henlius Biotech, Inc.: R&D Expenditure, $Million, 2019-2021
Figure 52: Lee's Pharmaceutical Limited: Product Portfolio
Figure 53: Lee's Pharmaceutical Limited: Overall Financials, $Million, 2019-2021
Figure 54: Lee's Pharmaceutical Limited: R&D Expenditure, $Million, 2019-2021
Figure 55: Jiangsu Hengrui Pharmaceuticals Co., Ltd.: Product Portfolio
Figure 56: Jiangsu Hengrui Pharmaceuticals Co., Ltd.: Overall Financials, $Million, 2019-2021
Figure 57: Jiangsu Hengrui Pharmaceuticals Co., Ltd.: R&D Expenditure, $Million, 2019-2021
Figure 58: Beigene Ltd.: Product Portfolio
Figure 59: Beigene Ltd.: Overall Financials, $Million, 2019-2021
Figure 60: Beigene Ltd.: R&D Expenditure, $Million, 2019-2021

12. 12
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
E
X
T
E
N
S
I
V
E
S
T
A
G
E
S
M
A
L
L
C
E
L
L
L
U
N
G
C
A
N
C
E
R
M
A
R
K
E
T
List of Tables
Table 1: Extensive Stage Small Cell Lung Cancer Prevalence in Seven Major Markets, 2022-2032
Table 2: Global Extensive Stage Small Cell Lung Cancer Market Snapshot
Table 3: HLX-10 (Serplulimab/Hansizhuang) from Shanghai Henlius Biotech in Comparison with
Approved Products of the Global Extensive Stage Small Cell Lung Cancer Market
Table 4: Jiangsu Hengrui Pharmaceuticals Co., Ltd. Extensive Stage Small Cell Lung Cancer Pipeline
Table 5: Competitive Landscape Snapshot
Table 6: Potential Immune Checkpoint Inhibitors Under Clinical Development
Table 7: Different Drug Classes Under Development for Treatment of Extensive Stage Small Cell Lung
Cancer
Table 8: Veterans’ Administration (VA) Lung Group Classification Scheme
Table 9: Advantages and Disadvantages of Chemotherapy Treatment
Table 10: Advantages and Disadvantages of Radiation Therapy
Table 11: FDA Approved Immunotherapies for Treatment of Extensive Stage Small Cell Lung Cancer
Table 12: Advantages and Disadvantages of Immunotherapy
Table 13: NCCN and NICE Treatment Guidelines
Table 14: Clinical Trials by Route of Administration (RoA)
Table 15: Combination Therapies Under Clinical Trial
Table 16: Leading Monotherapies Under Clinical Trial
Table 17: Marketed Products Indicated for the Treatment of Extensive Stage Small Cell Lung Cancer
Table 18: Zepzelca (Lurbinectedine) Key Regulatory Events
Table 19: Promising Products in Development
Table 20: Clinical Trial Details of HLX-10 (Serplulimab/Hansizhuang)
Table 21: Clinical Trial Details of HLX-10
Table 22: Clinical Trial Details of Socazolimab (ZKAB001)
Table 23: Clinical Trial Details of SHR-1316 (Adebrelimab)
Table 24: Phase Three Clinical Trial Result of SHR-1316 (Adebrelimab)
Table 25: F. Hoffmann-La Roche Ltd: Key Competitors
Table 26: AstraZeneca PLC: Key Competitors
Table 27: Shanghai Henlius Biotech, Inc.: Key Competitors
Table 28: Lee's Pharmaceutical Limited: Key Competitors
Table 29: Jiangsu Hengrui Pharmaceuticals Co., Ltd.’s Extensive State SCLC Products’ Clinical Trials

13. 13
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
E
X
T
E
N
S
I
V
E
S
T
A
G
E
S
M
A
L
L
C
E
L
L
L
U
N
G
C
A
N
C
E
R
M
A
R
K
E
T
Table 30: Jiangsu Hengrui Pharmaceuticals Co., Ltd.: Key Competitors
Table 31: Beigene Ltd.: Key Competitors

14. 14
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
E
X
T
E
N
S
I
V
E
S
T
A
G
E
S
M
A
L
L
C
E
L
L
L
U
N
G
C
A
N
C
E
R
M
A
R
K
E
T
BIS Research Offerings:
We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s
digital age. We have a vision to be a leading and preferred knowledge partner for corporates and institutions
worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other
innovative solutions.
Know More Know More
Know More
Know More

15. 15
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
E
X
T
E
N
S
I
V
E
S
T
A
G
E
S
M
A
L
L
C
E
L
L
L
U
N
G
C
A
N
C
E
R
M
A
R
K
E
T
Disclaimer
BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to
orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth.
This document and its contents are confidential and may not be further distributed, published or reproduced,
in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS
Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly
through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information
to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce
Information in legal proceedings.
Market reports are based on expectations, estimates and projections as of the date such information is
available. Any recommendation contained in this report may not be suitable for all investors or businesses.
The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while
considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to
market fluctuations and business, economic and competitive uncertainties and contingencies
For more details regarding permission, please contact us:
Email: sales@bisresearch.com
Tel: +1 510 404 8135

16. 16
All rights reserved at BIS Research Inc.
G
L
O
B
A
L
E
X
T
E
N
S
I
V
E
S
T
A
G
E
S
M
A
L
L
C
E
L
L
L
U
N
G
C
A
N
C
E
R
M
A
R
K
E
T
BIS RESEARCH INC.
39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686
E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135
Global Delivery Center
Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway,
Sector 126, Noida, U.P., 201303, India
Tel: +91 120 4261540 / 4261544
www.bisresearch.com